Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial.

Journal:
Journal of the American Society of Nephrology
Published:
DOI:
10.1681/asn.0000001076
Affiliations:
18
Authors:
17
Go to article
Institutions Authors Share
Novartis Pharmaceuticals Corporation, United States of America (USA)
4.000000
 0.24
Brazilian Society of Nephrology, Brazil
1.000000
 0.06
University of São Paulo (USP), Brazil
1.000000
 0.06
Novartis, Switzerland
1.000000
 0.06
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)
1.000000
 0.06
Monash Health, Australia
1.000000
 0.06
Federal University of São Paulo (UNIFESP), Brazil
1.000000
 0.06
Hallym University Sacred Heart Hospital, HUMC, South Korea
1.000000
 0.06
University of Malaya (UM), Malaysia
1.000000
 0.06
Hospital Sultanah Aminah (HSA), Malaysia
1.000000
 0.06
The George Institute for Global Health (TGI), Australia
0.666667
 0.04
University of New South Wales (UNSW Sydney), Australia
0.666667
 0.04
Leicester General Hospital, UHL, United Kingdom (UK)
0.500000
 0.03
University of Valencia (UV), Spain
0.500000
 0.03
Biomedical Research Institute (INCLIVA), Spain
0.500000
 0.03
University of Leicester, United Kingdom (UK)
0.500000
 0.03
University Medical Center Groningen (UMCG), RUG, Netherlands
0.333333
 0.02
Prince of Wales Hospital, Australia
0.333333
 0.02
Interested in Clinical Sciences?